Overview
- Bax24 met its primary endpoint with a statistically significant, placebo-adjusted 14.0 mmHg reduction in ambulatory 24-hour average systolic blood pressure at 12 weeks.
- Seventy-one percent of patients on baxdrostat achieved an ambulatory 24-hour systolic blood pressure below 130 mmHg versus 17% on placebo.
- Key secondary endpoints improved significantly, including night-time ambulatory systolic blood pressure and seated systolic blood pressure.
- Efficacy was sustained across the full 24 hours, including the higher-risk early morning period.
- Baxdrostat was generally well tolerated with a safety profile consistent with earlier BaxHTN data, and full Bax24 results were presented at the AHA Scientific Sessions 2025.